Literature DB >> 30375919

Roles of CDKs in RNA polymerase II transcription of the HIV-1 genome.

Andrew P Rice1.   

Abstract

Studies of RNA Polymerase II (Pol II) transcription of the HIV-1 genome are of clinical interest, as the insight gained may lead to strategies to selectively reactivate latent viruses in patients in whom viral replication is suppressed by antiviral drugs. Such a targeted reactivation may contribute to a functional cure of infection. This review discusses five Cyclin-dependent kinases - CDK7, CDK9, CDK11, CDK2, and CDK8 - involved in transcription and processing of HIV-1 RNA. CDK7 is required for Pol II promoter clearance of reactivated viruses; CDK7 also functions as an activating kinase for CDK9 when resting CD4+ T cells harboring latent HIV-1 are activated. CDK9 is targeted by the viral Tat protein and is essential for productive Pol II elongation of the HIV-1 genome. CDK11 is associated with the TREX/THOC complex and it functions in the 3' end processing and polyadenylation of HIV-1 transcripts. CDK2 phosphorylates Tat and CDK9 and this stimulates Tat activation of Pol II transcription. CDK8 may stimulate Pol II transcription of the HIV-1 genome through co-recruitment with NF-κB to the viral promoter. Some notable open questions are discussed concerning the roles of these CDKs in HIV-1 replication and viral latency.

Entities:  

Keywords:  CDK; CDK9; HIV; HIV latency; P-TEFb; Tat

Mesh:

Substances:

Year:  2018        PMID: 30375919      PMCID: PMC6602559          DOI: 10.1080/21541264.2018.1542254

Source DB:  PubMed          Journal:  Transcription        ISSN: 2154-1272


  10 in total

1.  Transcriptional CDKs in the spotlight.

Authors:  Joaquin M Espinosa
Journal:  Transcription       Date:  2019-04

2.  HIV Transcription Is Independent of Mediator Kinases.

Authors:  Daniele C Cary; Mona Rheinberger; Ajda Rojc; B Matija Peterlin
Journal:  AIDS Res Hum Retroviruses       Date:  2019-05-29       Impact factor: 2.205

3.  Reversible phosphorylation of cyclin T1 promotes assembly and stability of P-TEFb.

Authors:  Fang Huang; Trang Tt Nguyen; Ignacia Echeverria; Ramachandran Rakesh; Daniele C Cary; Hana Paculova; Andrej Sali; Arthur Weiss; Boris Matija Peterlin; Koh Fujinaga
Journal:  Elife       Date:  2021-11-25       Impact factor: 8.140

4.  Irreversible Loss of HIV-1 Proviral Competence in Myeloid Cells upon Suppression of NF-κB Activity.

Authors:  Rebecca J Peters; Mario Stevenson
Journal:  J Virol       Date:  2022-05-23       Impact factor: 6.549

5.  Biogenesis of P-TEFb in CD4+ T cells to reverse HIV latency is mediated by protein kinase C (PKC)-independent signaling pathways.

Authors:  Uri Mbonye; Konstantin Leskov; Meenakshi Shukla; Saba Valadkhan; Jonathan Karn
Journal:  PLoS Pathog       Date:  2021-09-16       Impact factor: 7.464

6.  Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer.

Authors:  Hanzhi Liang; Yue Zhu; Zhiyuan Zhao; Jintong Du; Xinying Yang; Hao Fang; Xuben Hou
Journal:  Front Pharmacol       Date:  2022-05-03       Impact factor: 5.988

Review 7.  Targeting HIV-1 proviral transcription.

Authors:  Alex Olson; Binita Basukala; Wilson W Wong; Andrew J Henderson
Journal:  Curr Opin Virol       Date:  2019-08-29       Impact factor: 7.121

Review 8.  Key Players in HIV-1 Transcriptional Regulation: Targets for a Functional Cure.

Authors:  Luisa Mori; Susana T Valente
Journal:  Viruses       Date:  2020-05-11       Impact factor: 5.048

Review 9.  Experimental Systems for Measuring HIV Latency and Reactivation.

Authors:  Koh Fujinaga; Daniele C Cary
Journal:  Viruses       Date:  2020-11-09       Impact factor: 5.048

10.  CVB3 VP1 interacts with MAT1 to inhibit cell proliferation by interfering with Cdk-activating kinase complex activity in CVB3-induced acute pancreatitis.

Authors:  Hongxia Zhang; Lingbing Zeng; Qiong Liu; Guilin Jin; Jieyu Zhang; Zengbin Li; Yilian Xu; Huizhen Tian; Shanshan Deng; Qiaofa Shi; Xiaotian Huang
Journal:  PLoS Pathog       Date:  2021-02-08       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.